Epigenetic metabolic reprogramming of right ventricular fibroblasts in pulmonary arterial hypertension : a pyruvate dehydrogenase kinase-dependent shift in mitochondrial metabolism promotes right ventricular fibrosis
Tian, Lian and Wu, Danchen and Dasgupta, Asish and Chen, Kuang-Hueih and Mewburn, Jeffrey and Potus, Francois and Lima, Patricia D.A. and Hong, Zhigang and Zhao, Yuan-Yuan and Hindmarch, Charles C.T. and Kutty, Shelby and Provencher, Steeve and Bonnet, Sebastien and Sutendra, Gopinath and Archer, Stephen L. (2020) Epigenetic metabolic reprogramming of right ventricular fibroblasts in pulmonary arterial hypertension : a pyruvate dehydrogenase kinase-dependent shift in mitochondrial metabolism promotes right ventricular fibrosis. Circulation Research, 126 (12). pp. 1723-1745. ISSN 0009-7330 (https://doi.org/10.1161/CIRCRESAHA.120.316443)
Preview |
Text.
Filename: Tian_etal_CR_2020_Epigenetic_metabolic_reprogramming_of_right_ventricular_fibroblasts.pdf
Accepted Author Manuscript Download (29MB)| Preview |
Abstract
Rationale: Right ventricular (RV) fibrosis in pulmonary arterial hypertension contributes to RV failure. While RV fibrosis reflects changes in the function of resident RV fibroblasts (RVfib), these cells are understudied. Objective: Examine the role of mitochondrial metabolism of RVfib in RV fibrosis in human and experimental pulmonary arterial hypertension. Methods and Results: Male Sprague-Dawley rats received monocrotaline (MCT; 60 mg/kg) or saline. Drinking water containing no supplement or the PDK (pyruvate dehydrogenase kinase) inhibitor dichloroacetate was started 7 days post-MCT. At week 4, treadmill testing, echocardiography, and right heart catheterization were performed. The effects of PDK activation on mitochondrial dynamics and metabolism, RVfib proliferation, and collagen production were studied in RVfib in cell culture. Epigenetic mechanisms for persistence of the profibrotic RVfib phenotype in culture were evaluated. PDK expression was also studied in the RVfib of patients with decompensated RV failure (n=11) versus control (n=7). MCT rats developed pulmonary arterial hypertension, RV fibrosis, and RV failure. MCT-RVfib (but not left ventricular fibroblasts) displayed excess mitochondrial fission and had increased expression of PDK isoforms 1 and 3 that persisted for >5 passages in culture. PDK-mediated decreases in pyruvate dehydrogenase activity and oxygen consumption rate were reversed by dichloroacetate (in RVfib and in vivo) or siRNA targeting PDK 1 and 3 (in RVfib). These interventions restored mitochondrial superoxide and hydrogen peroxide production and inactivated HIF (hypoxia-inducible factor)-1α, which was pathologically activated in normoxic MCT-RVfib. Redox-mediated HIF-1α inactivation also decreased the expression of TGF-β1 (transforming growth factor-beta-1) and CTGF (connective tissue growth factor), reduced fibroblast proliferation, and decreased collagen production. HIF-1α activation in MCT-RVfib reflected increased DNMT (DNA methyltransferase) 1 expression, which was associated with a decrease in its regulatory microRNA, miR-148b-3p. In MCT rats, dichloroacetate, at therapeutic levels in the RV, reduced phospho-pyruvate dehydrogenase expression, RV fibrosis, and hypertrophy and improved RV function. In patients with pulmonary arterial hypertension and RV failure, RVfib had increased PDK1 expression. Conclusions: MCT-RVfib manifest a DNMT1-HIF-1α-PDK–mediated, chamber-specific, metabolic memory that promotes collagen production and RV fibrosis. This epigenetic mitochondrial-metabolic pathway is a potential antifibrotic therapeutic target.
ORCID iDs
Tian, Lian ORCID: https://orcid.org/0000-0002-9699-8009, Wu, Danchen, Dasgupta, Asish, Chen, Kuang-Hueih, Mewburn, Jeffrey, Potus, Francois, Lima, Patricia D.A., Hong, Zhigang, Zhao, Yuan-Yuan, Hindmarch, Charles C.T., Kutty, Shelby, Provencher, Steeve, Bonnet, Sebastien, Sutendra, Gopinath and Archer, Stephen L.;-
-
Item type: Article ID code: 72645 Dates: DateEvent5 June 2020Published27 March 2020Published Online26 March 2020AcceptedSubjects: Medicine > Therapeutics. Pharmacology Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 09 Jun 2020 14:33 Last modified: 18 Dec 2024 13:09 URI: https://strathprints.strath.ac.uk/id/eprint/72645